#United States #Class Action #Los Angeles #Baxter International #BAX

Class Action Opportunity for Baxter International Shareholders

In a significant development for shareholders of Baxter International, Inc. (BAX), a leading global healthcare company, investors who have suffered financial losses are being given the opportunity to take charge of a securities fraud class action lawsuit. This legal initiative has been announced by the law firm Glancy Prongay & Murray LLP, which aims to hold the company accountable for alleged misconduct.

Background of the Lawsuit

The lawsuit concerns claims that, between February 23, 2022, and July 30, 2025, Baxter failed to reveal critical information regarding the Novum LVP infusion pumps, a significant product in its portfolio. According to the filed complaint, these devices reportedly experienced systematic defects that resulted in malfunctions, including improper infusion rates and even complete non-delivery of fluids to patients. Such failures have serious implications, potentially exposing patients to critical health risks including serious injury or death.

Moreover, the lawsuit alleges that Baxter was aware of these defects and had received notifications about multiple malfunctions, including incidents leading to injuries and fatalities. Despite this knowledge, the company’s efforts to remedy the situation through customer alerts were deemed insufficient, as design flaws persisted and continued to jeopardize patient safety.

The ramifications of these failures were severe, suggesting that Baxter’s customers might have been forced to remove existing Novum LVP units from service and halt any further sales of the product. Consequently, the lawsuit argues that the company’s positive statements about its operations and future prospects were materially misleading and lacked a reasonable foundation during this time frame.

Taking Action

Shareholders who experienced losses during this period are encouraged to take action by participating in the lawsuit. Interested parties must click on the relevant link before December 15, 2025, to ensure their involvement as lead plaintiffs or witnesses in this class action. Investing in smaller companies and healthcare stocks carries inherent risks, and this case could set a precedent regarding corporate accountability in the medical equipment sector.

For more information, or if you have questions about your rights or interests regarding this lawsuit, reach out to Charles Linehan, Esq., at Glancy Prongay & Murray LLP. The firm offers resources to understand the intricacies of the legal process and what it entails for affected shareholders.

Contact Information

To inquire about the case, contact:

• - Charles Linehan, Esq.

Glancy Prongay & Murray LLP
1925 Century Park East, Suite 2100,
Los Angeles, CA 90067
Email: [email protected]
Phone: 310-201-9150
Toll-Free: 888-773-9224

This represents a critical opportunity for Baxter shareholders to reclaim their losses and potentially transform their frustrations into a collective legal action aimed at justice and corporate responsibility. As this case unfolds, it may provide insights into the governance and operational ethics of major healthcare companies, especially regarding their accountability to patients and shareholders alike.

In summary, Baxter International, Inc. shareholders who have lost money due to the company’s alleged failure to disclose significant product defects now have the opportunity to actively participate in a legal proceeding designed to seek reparations. As the deadline approaches, affected investors are urged to act quickly and consult with legal professionals if they wish to be part of the ongoing fight for accountability in the healthcare sector.